Organisation paid for research Program year 2025 Source: CMS Open Payments

Allegheny Health Network

Neither a doctor nor a teaching hospital

Research payments

$1,208,700

209 payments

Through program year 2025, Allegheny Health Network is reported as receiving $1,208,700 in research payments, across 209 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $656,848 114
2024 Research $143,059 41
2023 Research $228,044 16
2022 Research $111,859 27
2021 Research $66,487 7
2020 Research $257 2
2019 Research $2,146 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $437,243 10 payments
  2. Merck Sharp & Dohme Corporation $280,197 12 payments
  3. Karyopharm Therapeutics Inc. $116,259 66 payments
  4. GT Medical Technologies, Inc $72,095 42 payments
  5. Iovance Biotherapeutics, Inc. $60,600 1 payment
  6. Silk Road Medical, Inc. $47,960 15 payments
  7. Volta Medical Inc $42,400 9 payments
  8. E.R. Squibb & Sons, L.L.C. $38,009 11 payments
  9. Novartis Pharmaceuticals Corporation $36,799 8 payments
  10. Inari Medical, Inc. $30,465 19 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 $280,197 12 payments
  2. A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis $147,822 2 payments
  3. A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma $116,259 66 payments
  4. A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) $112,858 1 payment
  5. Fast TILs to Treat Metastatic Cancer Patients with Pleural Disease: A Phase I Trial $60,600 1 payment
  6. A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) $51,461 1 payment
  7. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) $47,297 1 payment
  8. Gtm-102 $46,690 34 payments
  9. A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients $42,052 2 payments
  10. Roadster 3 $37,420 18 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $25,483 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record